Skip to main content
OpenTrials
Completed

NCT Number: NCT01343719

Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.

The objective of the current study is to investigate safety, tolerability, and pharmacokinetics of treatment with BI 661051 rising single doses administered as oral drinking solution (powder in bottle) in healthy male subjects.

The primary objective is to investigate the safety and tolerability of treatment with BI 661051.

The secondary objectives are (1) to evaluate the single dose pharmacokinetics of BI 661051, (2) to explore dose proportionality, (3) to explore the relative bioavailability when BI 661051 is administered as tablet at two dose levels compared to oral drinking solution and (4) to assess the effect on the bioavailability when BI 661051 is administered as oral drinking solution after intake of a high fat meal.

Pharmacodynamic parameters will not be determined within this study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

1296.1.1 Boehringer Ingelheim Investigational Site

Mannheim, Germany

About this study

Purpose:

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy males based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests. There is no finding deviating from normal and of clinical relevance. There is no evidence of a clinically relevant concomitant disease.
  • Age =18 and age =50 years.
  • BMI =18.5 and BMI =30 kg/m2 (Body Mass Index).
  • Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation.

Exclusion criteria

  • Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance.
  • Any evidence of a clinically relevant concomitant disease.
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.
  • History of relevant orthostatic hypotension, fainting spells or blackouts.
  • Chronic or relevant acute infections.
  • History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) as judged clinically relevant by the investigator.
  • Intake of drugs with a long half-life (>24 h) within at least 1 month or less than 10 half-lives of the respective drug prior to administration.
  • Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to randomisation.
  • Participation in another trial with an investigational drug within 30 days prior to randomisation.
  • Smoker (>10 cigarettes or >3 cigars or >3 pipes/day).
  • Inability to refrain from smoking on trial days as judged by the investigator.
  • Alcohol abuse (more than 30 g/day).
  • Drug abuse.
  • Blood donation (more than 100 mL within 4 weeks prior to randomisation or during the trial).
  • Excessive physical activities (within 1 week prior to randomisation or during the trial).
  • Any laboratory value outside the reference range that is of clinical relevance.
  • Inability to comply with dietary regimen of the study centre.

Treatment and study plan

BI 661051

Drug

medium dose solution for oral administration

Placebo

Drug

solution for administration

Primary outcomes

  1. Occurrence of findings of physical examination

    Time frame: 14 weeks

  2. Vital signs (blood pressure (BP), pulse rate (PR), respiratory rate [RR])

    Time frame: 14 weeks

  3. Orthostasis test parameters

    Time frame: 14 weeks

  4. Body temperature

    Time frame: 14 weeks

  5. 12-lead electrocardiogram (ECG) parameters (heart rate, PQ interval, QRS interval, uncorrected QT interval as well as Bazett- and Fridericia corrected QT interval)

    Time frame: 14 weeks

  6. Clinical laboratory test parameters (haematology, clinical chemistry and urinalysis parameters)

    Time frame: 14 weeks

  7. Occurrence of adverse events (AEs) on the level of Medical Dictionary for Regulatory Affairs (MedDRA) Preferred Terms and MedDRA System Organ Class

    Time frame: 14 weeks

  8. Occurrence of findings detected by the pupillometry measurements

    Time frame: 14 weeks

  9. Tolerability assessed by investigator

    Time frame: 14 weeks

Secondary outcomes

  1. Cmax (maximum measured concentration of the analyte in plasma)

    Time frame: 14 weeks

  2. AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: 14 weeks

  3. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable analyte plasma concentration)

    Time frame: 14 weeks

  4. Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2)

    Time frame: 14 weeks

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Phase I Study to a) Assess Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of 2 mg to 350 mg of BI 661051 Administered as Oral Drinking Solution (Powder in Bottle) in Healthy Male Volunteers, b) to Explore the Relative Oral Bioavailability of a Tablet Formulation and c) to Assess the Impact of a High Fat Meal on the Oral Bioavailability of the Oral Drinking Solution (Powder in Bottle)

Important dates

Study start
2011
Primary completion
2011
First posted
Apr 28, 2011
Registry last updated
Oct 31, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.